905 related articles for article (PubMed ID: 24419920)
1. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging bladder cancer urinary biomarkers.
Parker J; Spiess PE
ScientificWorldJournal; 2011 May; 11():1103-12. PubMed ID: 21623456
[TBL] [Abstract][Full Text] [Related]
3. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.
Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359
[TBL] [Abstract][Full Text] [Related]
4. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive diagnostic tests for bladder cancer: a review of the literature.
Bassi P; De Marco V; De Lisa A; Mancini M; Pinto F; Bertoloni R; Longo F
Urol Int; 2005; 75(3):193-200. PubMed ID: 16215303
[TBL] [Abstract][Full Text] [Related]
6. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
7. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
Raitanen MP;
World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
[TBL] [Abstract][Full Text] [Related]
8. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.
Golijanin D; Sherman Y; Shapiro A; Pode D
Urology; 1995 Aug; 46(2):173-7. PubMed ID: 7624989
[TBL] [Abstract][Full Text] [Related]
9. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
Wiener HG; Mian C; Haitel A; Pycha A; Schatzl G; Marberger M
J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
Abd El Gawad IA; Moussa HS; Nasr MI; El Gemae EH; Masooud AM; Ibrahim IK; El Hifnawy NM
J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
[TBL] [Abstract][Full Text] [Related]
12. Urine cytology. It is still the gold standard for screening?
Brown FM
Urol Clin North Am; 2000 Feb; 27(1):25-37. PubMed ID: 10696242
[TBL] [Abstract][Full Text] [Related]
13. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder.
Bhuiyan J; Akhter J; O'Kane DJ
Clin Chim Acta; 2003 May; 331(1-2):69-77. PubMed ID: 12691866
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
15. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
16. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
[TBL] [Abstract][Full Text] [Related]
17. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
18. Human complement factor H related protein test for monitoring bladder cancer.
Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
